Incidence, characteristics, and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000 to 2013.
BACKGROUND
Recent incidence, treatment patterns, and outcomes for node negative microscopically invasive breast cancer (MIBC) have not been reported.


METHODS
State Health Registry of Iowa data identified women with ductal carcinoma in situ (DCIS), MIBC, and stage I breast cancer excluding MIBC (stage 1BC).


RESULTS
From 2000 to 2013, 1,706, 193, and 4,514 women were diagnosed with DCIS, MIBC, and stage 1BC, respectively. MIBC increased at an annual percentage change of 2.1 (P = .041). MIBC was more frequently human epidermal growth factor receptor 2 positive than stage 1BC (39.7% vs 9.6%, P < .001). Mastectomy was performed more frequently in MIBC than DCIS (40.9% vs 30.6%, P = .014) or stage 1BC (40.9% vs 33.8%, P = .119). Chemotherapy was given to 4.1% of women with MIBC. Survival for women with MIBC was intermediate between DCIS and stage 1BC.


CONCLUSIONS
Management of MIBC is an increasingly frequent clinical scenario. Women with MIBC receive more aggressive local and systemic therapy than women with DCIS.
Division of Hematology, Oncology and Blood and Marrow Transplantation, Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Alexandra
A
Thomas
Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Ronald J
RJ
Weigel
Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, USA.
Charles F
CF
Lynch
Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Philip M
PM
Spanheimer
Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Elizabeth K
EK
Breitbach
Division of Health Services Research, Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City, IA, USA. Electronic address: mary-schroeder@uiowa.edu.
Mary C
MC
Schroeder
D001943:Breast Neoplasms / Q000737:chemistry / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000737:chemistry / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D005260:Female; D006801:Humans; D015994:Incidence; D007484:Iowa; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D018426:SEER Program
D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
Breast neoplasms; Cancer incidence; Mastectomy; Microinvasive tumor; SEER program
Tumour Biol. 2015 Apr;36(4):2241-8
25801239
Ann Surg Oncol. 2011 May;18(5):1342-8
21042943
Pathol Oncol Res. 2008 Jun;14(2):105-11
18493870
Ann Surg Oncol. 2014 Oct;21(10):3330-5
25092160
Arch Surg. 1990 Oct;125(10):1298-301; discussion 1301-2
2171453
Clin Breast Cancer. 2015 Feb;15(1):e27-34
25245424
BMC Res Notes. 2014 May 31;7:325
24884941
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):7-13
20950955
Eur J Radiol. 2010 Jan;73(1):102-7
19026501
J Natl Cancer Inst. 2010 May 5;102(9):627-37
20427430
Lancet. 2016 Feb 27;387(10021):849-56
26686957
Isr Med Assoc J. 2010 May;12(5):290-5
20929083
Surg Gynecol Obstet. 1993 Oct;177(4):425-40
8211592
Am J Surg. 2000 Oct;180(4):305-8
11113441
Am J Surg. 2003 Aug;186(2):112-6
12885600
Cancer. 1990 Jul 1;66(1):102-8
2162238
Ann Surg Oncol. 2013 Mar;20(3):811-8
22956068
BMC Cancer. 2010 Oct 15;10:557
20946688
Arch Surg. 1989 Jan;124(1):29-32
2535928
Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1386-9
19383888
Ann Surg Oncol. 2010 Jun;17(6):1471-4
20180029